Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Uveitis Market to Witness Upsurge in Growth at a CAGR of 4.8% During the Study Period (2019-2032), Assesses DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

03 May, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The uveitis market is expected to increase owing to the increasing awareness, improved diagnosis, and rising diagnosed prevalent population. In addition, the expected launch of emerging therapies, such as TRS01 (Tarsier Pharma), OCS-02(Oculis), RG6179 (Roche), and others, shall create a positive impact on the uveitis market.

LAS VEGAS, May 3, 2023 /PRNewswire/ -- DelveInsight's Uveitis Market Insights report includes a comprehensive understanding of current treatment practices, uveitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Uveitis Market Report

  • As per DelveInsight analysis, the uveitis market size in the 7MM was approximately USD 1.4 billion in 2022.
  • According to the assessment done by DelveInsight, the estimated total diagnosed prevalent uveitis cases in the 7MM were approximately 1 million in 2022. 
  • Leading uveitis companies such as Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Inc, Santen Inc., ABIONYX Pharma, OKYO Pharma, and others are developing novel uveitis drugs that can be available in the uveitis market in the coming years.
  • The promising uveitis therapies in the pipeline include TRS01, OCS-02 (licaminlimab), RG6179, Baricitinib, Izokibep, EYS606, Brepocitinib, OCS-01, Sirolimus (DE-109), CER 001, OK 101, and others.

Discover which therapies are expected to grab the major uveitis market share @ Uveitis Market Report

Uveitis Overview

Uveitis refers to a wide range of inflammatory ocular disorders. The National Cancer Institute defines uveitis as a rare condition in which all or part of the uvea (middle layer of the eye wall) becomes inflamed. The uvea comprises the choroid, the ciliary body, and the iris. Uveitis can also affect the lens, retina, optic nerve, and vitreous humor. It can be caused by an injury, infection, eye tumor, or an autoimmune or inflammatory disorder. One or both eyes may be impacted.

The signs and uveitis symptoms include redness and pain in the eye, sensitivity to light, impaired vision, dark floating areas in the vision, and vision loss. Furthermore, the uveitis symptoms may appear unexpectedly and rapidly worsen. If left untreated, uveitis can cause tissue damage and blindness. A comprehensive eye exam is required for uveitis diagnosis. The clinical uveitis diagnosis is frequently predicated on spillover inflammation (i.e., cell and protein flare) visible with a slit lamp in the aqueous or vitreous humor.

Uveitis Epidemiology Segmentation

DelveInsight estimates that there were approximately 1 million diagnosed prevalent cases of uveitis in the 7MM in 2022.

According to estimates based on DelveInsight's analysis, the US accounted for nearly 38% of the total diagnosed prevalent cases of uveitis in the 7MM in 2022, which is expected to increase further by 2032.

The uveitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Uveitis Diagnosed Prevalent Cases
  • Uveitis Type-specific Diagnosed Prevalent Cases
  • Uveitis Diagnosed Prevalent Cases by Anatomical Location
  • Uveitis Etiology-specific Diagnosed Prevalent Cases
  • Total Diagnosed Prevalent Cases of Macular Edema Associated With Uveitis

Download the report to understand which factors are driving uveitis epidemiology trends @ Uveitis Epidemiological Insights

Uveitis Treatment Market 

Current uveitis treatment options include oral corticosteroids, corticosteroid eye drops, and immunosuppressants such as Azathioprine, Cyclosporine, and Methotrexate. Immunosuppressive drugs are given orally in combination with prednisolone to treat chronic uveitis and reduce the incidence of second eye involvement. They have been effective in treating chronic uveitis in people with eye illnesses. Azathioprine has been shown to treat uveitis associated with Behcet illness effectively. Nonsteroidal immunosuppressant cyclosporine medications are used as a second-line uveitis treatment. Methotrexates are used to treat uveitis associated with juvenile idiopathic arthritis.

The use of biologics and surgery for chronic uveitis treatment has been reported. If a patient has recurrent floaters that impair their vision, the vitreous humor in the eye may be surgically repaired. Adalimumab and Infliximab, recombinant human igG1 monoclonal antibodies, may be used to treat noninfectious intermediate, posterior, or pan uveitis and chronic noninfectious uveitis.

While oral corticosteroids (tablets or capsules) are the most potent type of corticosteroids, they can have several side effects in addition to relieving inflammation. As a result, they should only be used if uveitis affects both eyes or interferes with everyday activities and other therapies have failed. There are now four corticosteroid medications available via distinct modes of administration, including Durezol (difluprednate ophthalmic emulsion), Triesence (triamcinolone acetonide), Retisert (fluocinolone acetonide implant), and Ozurdex (dexamethasone). The use of biologics and surgical treatment for chronic uveitis has been reported. If a patient has recurrent floaters that impair their vision, the vitreous humor in the eye may be surgically repaired.

To know more about uveitis treatment guidelines, visit @ Uveitis Management 

Uveitis Pipeline Therapies and Key Companies

  • TRS01: Tarsier Pharma
  • OCS-02 (licaminlimab): Oculis Pharma
  • RG6179: Roche
  • Baricitinib: Eli Lilly and Company
  • Izokibep: Acelyrin/Affibody Medical
  • EYS606: Eyevensys
  • Brepocitinib: Priovant Therapeutics, Inc.
  • OCS-01: Oculis Pharma
  • Sirolimus (DE-109): Santen Inc.
  • CER 001: ABIONYX Pharma
  • OK 101: OKYO Pharma

Learn more about the FDA-approved drugs for uveitis @ Drugs for Uveitis Treatment 

Uveitis Market Dynamics

The uveitis market dynamics are anticipated to change in the coming years due to increasing awareness, improved diagnosis, and rising diagnosed prevalent population. Recently, new medications with varied modes of action and delivery routes have been approved, enhancing the therapy regimen and boosting the uveitis market. In addition, companies can use the knowledge gained from recent developments in understanding the etiologies of uveitis to explore medicines with novel targets. Moreover, advances in disease nomenclature for classification, clinical trials, medication delivery systems, multimodality diagnostic imaging, and laboratory testing utilizing "omics" technology have all contributed to a better understanding of illness pathophysiology. Furthermore, biomarker identification and proteomics give possible targets for therapeutic intervention by available and accessible medications and information concerning pharmaceuticals that should be avoided.

However, several factors are impeding the growth of the uveitis market. The current treatment regimen is accompanied by adverse events and side effects that reduce its efficacy. Moreover, delays in diagnosis frequently lead to delays in therapy, resulting in poor visual outcomes. The condition manifests in various ways, with individuals reporting an incomplete history, frequently delaying diagnosis. Furthermore, emerging gene therapy may confront access and reimbursement challenges in the uveitis market due to its predicted high cost. Additionally, many medications are used off-label, and only a few have been studied in randomized controlled studies. Moreover, the development of effective medicines is complicated by etiological heterogeneity and thus causing a dip in the growth of the uveitis market.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]

Base Year

2019

Uveitis Market CAGR

4.8 %

Uveitis Market Size in 2022

USD 1.4 Billion

Key Uveitis Companies

Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Inc, Santen Inc., ABIONYX Pharma, OKYO Pharma, and others

Key Pipeline Uveitis Therapies

TRS01, OCS-02 (licaminlimab), RG6179, Baricitinib, Izokibep, EYS606, Brepocitinib, OCS-01, Sirolimus (DE-109), CER 001, OK 101, and others

Scope of the Uveitis Market Report

  • Therapeutic Assessment: Uveitis current marketed and emerging therapies
  • Uveitis Market Dynamics: Attribute Analysis of Emerging Uveitis Drugs 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Uveitis Market Access and Reimbursement

Discover more about uveitis drugs in development @ Uveitis Clinical Trials

Table of Contents

1.

Uveitis Market Key Insights

2.

Uveitis Market Report Introduction

3.

Uveitis Market Overview at a Glance

4.

Uveitis Market Executive Summary

5.

Disease Background and Overview

6.

Uveitis Treatment and Management

7.

Uveitis Epidemiology and Patient Population

8.

Patient Journey

9.

Uveitis Marketed Drugs

10.

Uveitis Emerging Drugs

11.

7MM Uveitis Market Analysis

12.

Uveitis Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Unmet Needs

16.

SWOT Analysis

17.

Appendix

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

Related Reports

Uveitis Pipeline

Uveitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key uveitis companies, including Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, among others.

Uveitis Epidemiology Forecast

Uveitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted uveitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Anterior Uveitis Market

Anterior Uveitis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anterior uveitis companies, including Novartis AG, Santen Pharmaceutical Co., Ltd; AbbVie Inc., Eyegate Pharmaceuticals, Inc., Clearside Biomedical, Inc., Aldeyra Therapeutics, Inc., among others.

Anterior Uveitis Pipeline

Anterior Uveitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anterior uveitis companies, including Novartis AG, Santen Pharmaceutical Co., Ltd; AbbVie Inc., Eyegate Pharmaceuticals, Inc., Clearside Biomedical, Inc., Aldeyra Therapeutics, Inc., among others.

Anterior Uveitis Epidemiology Forecast

Anterior Uveitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted anterior uveitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.